+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
Pulmonary Arterial Hypertension (PAH) is a rare disease, which affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease usually grows worse over the period and may result to death if left untreated.
Market players are focusing on collaborations & mergers to develop novel products in the pulmonary arterial hypertension (PHA) market, which is expected to boost growth of the market over the forecast period. For instance, in 2017, Bayer AG and Vectura Group Plc. extended their collaboration to develop an upgraded version of nebulizer Breelib, which improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. Moreover, according to the National Institute of Health, the nebulizer is still in clinical trial and the study is expected to finish by March 2020.
Furthermore, ongoing regulatory approvals for the products by the market players is expected to fuel the market growth over the forecast period. For instance, in March 2016, Actelion Pharmaceuticals Ltd, the Janssen Pharmaceutical Companies of Johnson & Johnson Services Inc., received the approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. The Medicines and Medical Devices Safety Authority (Medsafe) approved the drug in the New Zealand and the Therapeutic Goods Administration (TGA) approved in Australia.
The global pulmonary arterial hypertension (PAH) market was valued at US$ 5,821.90 million in 2018, and is expected to exhibit a CAGR of 5.9% over the forecast period (2019-2027).
Figure 1. Global Pulmonary Arterial Hypertension (PHA) Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Rising cases of heart problems leading to pulmonary arterial hypertension (PHA) is expected to boost growth of the global pulmonary arterial hypertension (PHA) market
The global pulmonary arterial hypertension (PHA) market is expected to witness significant growth over the forecast period, owing to rising cases of heart disorders, which leads to pulmonary arterial hypertension (PHA). For instance, according to the Center for Disease Control and Prevention (CDC), a report- Prevalence of uncontrolled risk factors for cardiovascular disease – May 2019 states that, in the U.S. someone has a heart attack every 40 seconds. The report also states that each year, around 805,000 people in the U.S. have a heart attack.
Figure 2. Global Pulmonary Arterial Hypertension (PHA) Market Share (%), by Drug Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Increasing collaborations for novel product development and rising cases of pulmonary hypertensions are expected to drive the market growth
North America is expected to hold a dominant position in the global pulmonary arterial hypertension (PHA) market, owing to increasing strategic partnerships and collaborations by key players, which is expected to drive the North America market growth over the forecast period. For instance, in September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. These companies also aimed to enter in a research agreement for the conduct of research by MannKind. This research was had to be performed by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.
Moreover, Europe is expected to be the second dominating region in the global pulmonary arterial hypertension (PHA) market, owing to rising cases of pulmonary arterial hypertension (PHA) in the region. For instance, according to the Health and Social Care Information Centre, National Audit of Pulmonary Hypertension - 2015, the study published in 2016 reports that 57.0% of patients were treated with pulmonary hypertension drug therapy in Great Britain, 56.0% in England, 63.0% in Scotland, and 73.0% in Wales.
Key Players
Major players operating in the global pulmonary arterial hypertension (PHA) market include United Therapeutics Corporation, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company, Limited.
Pulmonary arterial hypertension is a rare diseases that is caused due to various factors such as congestive heart failure, liver diseases, autoimmune diseases, which includes Lupus, scleroderma, rheumatoid arthritis, and others. This disease is considered rare but life-threatening condition that gets worse over time. The narrowed and blocked arteries with the high pressure of blood is called as pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH). The tiny arteries in the lungs become narrow and blocked, which makes difficult to pump blood through these arteries and later leads to weaken the heart muscle. Rising cases of causes of pulmonary arterial hypertension (PAH) is expected to fuel growth of the market in the forecast period. For instance, according to the American College of Cardiology Foundation published an article Heart Disease and Stroke Statistics-2019, a report from the American Heart Association, around 795,000 U.S. population have a new or recurrent stroke annually, in which 90.0% of stroke risk is due to modifiable risk factors and 74.0% is due to behavioral risk factors.
Furthermore, approvals of drugs through the regulatory bodies for the treatment of pulmonary arterial hypertension (PAH) are expected to fuel growth of the market. For instance, in September 2017, Actelion Pharmaceuticals, Ltd. received a New Drug Application (NDA) approval from the U.S. Food and Drug Administration for Tracleer (bosentan), a 32 mg dispersible tablets. This drug got approval for the treatment of Pulmonary Arterial Hypertension in adult and pediatric patients.
Market Dynamics
The pulmonary arterial hypertension (PAH) market is expected to witness significant growth over the forecast period, owing to increasing number of heart failures which later leads to pulmonary arterial hypertension (PAH) cases. For instance, in 2019, Heart Failure Society of America reports that around 550,000 new cases of heart failure are diagnosed each year in the U.S. and nearly 1.4 million persons with congestive heart failure (CHF) are under 60 years of age.
Product approvals by regulatory authorities are expected to drive growth of pulmonary arterial hypertension (PAH) market over the forecast period. For instance, in 2013, the U.S. Food and Drug Administration approved Actelion Ltds’ Opsumit (Macitentan) for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. The drug is novel dual endothelin receptor antagonist (ERA), a 10 mg oral tablet available to address efficacy and safety.
Moreover, in November 2018, Arena Pharmaceuticals and United Therapeutics entered into an exclusive license agreement related to Ralinepag (Potent IP Receptor Agonist), which was evaluated for the treatment of pulmonary arterial hypertension. Under the agreement, United Therapeutics got an exclusive and irrevocable license to develop, manufacture and commercialize ralinepag in any formulation for pulmonary arterial hypertension (PAH).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
